Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

J Thromb Thrombolysis. 2019 Jan;47(1):155-156. doi: 10.1007/s11239-018-1773-4.

Authors

Roberto Castelli¹, Paolo Gallipoli², Riccardo Schiavon³, Thomas Teatini³, Giorgio Lambertenghi Deliliers⁴, Luigi Bergamaschini³

Affiliations

¹ Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy. roberto.castelli@unimi.it.
² Department of Haematology, Cambridge Institute for Medical Research, Cambridge University, Cambridge, UK.
³ Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy.
⁴ Fondazione Matarelli Milano, Milan, Italy.

PMID: 30478722
DOI: 10.1007/s11239-018-1773-4

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Heparin / adverse effects*
Homozygote
Humans
Janus Kinase 2 / genetics*
Male
Middle Aged
Mutation, Missense*
Risk
Thrombocythemia, Essential / genetics*
Thrombocytopenia / chemically induced*
Thrombosis / chemically induced*

Substances

Heparin
JAK2 protein, human
Janus Kinase 2